Innoviva, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
INVA
Innoviva, INCInnoviva, Inc. has expanded its financial commitment to Armata Pharmaceuticals through a new $25 million secured credit agreement.
NASDAQ
INVA
Innoviva, INCSCHEDULE 13D/A: Armata Extends Key Debt, Warrants, and Voting Agreements
Armata Pharmaceuticals, Inc. and Innoviva, Inc. have extended maturity dates for several credit agreements and expiration dates for warrants and a voting agreement, solidifying their financial relationship.
NASDAQ
INVA
Innoviva, INCInnoviva, Inc. and its subsidiary have increased their beneficial ownership in Armata Pharmaceuticals to 83.3% and provided a new $15 million secured loan.
NASDAQ
INVA
Innoviva, INCSCHEDULE 13D/A: Sarissa Capital Significantly Reduces Innoviva Stake, Exiting Major Shareholder Status
Sarissa Capital Management LP and Alexander J. Denner have significantly reduced their beneficial ownership in Innoviva, Inc. to below 5%, ceasing to be subject to certain SEC reporting requirements.
NASDAQ
INVA
Innoviva, INCSCHEDULE 13D/A: Innoviva Extends Significant Funding and Debt Maturities for Armata Pharmaceuticals, Increasing Stake to 85.2%
Innoviva, Inc. and its subsidiary have provided Armata Pharmaceuticals with a new $10 million secured loan and extended the maturity dates of three existing credit agreements to March 2026, solidifying their beneficial ownership to 85.2%.
NASDAQ
INVA
Innoviva, INCSarissa Capital Management LP and its Chief Investment Officer, Alexander J. Denner, have significantly reduced their beneficial ownership in Innoviva, Inc., disposing of over 2 million shares in early March 2025, bringing their stake down to 8.4%.